Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Webcast
1 AMA PRA Category 1 Credit™ ...OVERVIEW
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease is organized by Paradigm Medical Communications, LLC.
Release Date: April 15, 2024
Expiration Date: April 15, 2025
Description:
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways-VEGF-A and angiopoietin-2 (Ang-2)-is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Describe the significance of Ang-2 inhibition in combination with VEGF-A inhibition in the development and progression of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)
- Distinguish dual inhibition therapy from anti-VEGF therapy based on anatomic effects
- Individualize the use of dual inhibition therapy in patients with nAMD, DME, and RVO based on patient and disease characteristics, including response to previous therapy when applicable, using the best available evidence
ACCREDITATION & CREDITS
Physician Accreditation Statement:
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement:
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education:
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
TARGET AUDIENCE
PhysicianOphthalmologistVascular Medicine SpecialistsSPECIALITIES
OphthalmologyVascular Disease
Quick Links